GSK 3191607

Drug Profile

GSK 3191607

Alternative Names: [14C] - GSK 3191607; GSK3191607

Latest Information Update: 22 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antimalarials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Falciparum malaria

Most Recent Events

  • 01 May 2016 GlaxoSmithKline completes a phase I trial in Falciparum malaria (In volunteers) in United Kingdom (IV) (NCT02737007)
  • 07 Apr 2016 GlaxoSmithKline plan a phase I trial in Healthy male volunteers in United Kingdom (IV) (NCT02737007)
  • 01 Apr 2016 Phase-I clinical trials in Falciparum malaria (In volunteers) in United Kingdom (IV) (NCT02737007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top